Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Liu, Zhen ^a   Li, Lixia ^b   Yang, Zhixiong ^b   Luo, Weiren ^b   Li, Xin ^a   Yang, Huiling ^c   Yao, Kaitai ^a   Wu, Bin ^b   Fang, Weiyi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MESSENGER RNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SURVIVAL TIME; CARCINOMA; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; TIME; UPREGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; YOUNG ADULT;

EID: 77953191275     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-270     Document Type: Article

References (26)

1. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007, 6:1. 10.1186/1476-4598-6-1, 1774581, 17199893.
2. Fang W, Li X, Jiang Q, Liu Z, Yang H, Wang S, Xie S, Liu Q, Liu T, Huang J, et al. Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008, 6:32. 10.1186/1479-5876-6-32, 2443113, 18570662.
3. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995, 55(12):2548-2555.
4. Backstrom JR, Tokes ZA. The 84-kDa form of human matrix metalloproteinase-9 degrades substance P and gelatin. J Neurochem 1995, 64(3):1312-1318.
5. Xie SM, Fang WY, Liu Z, Wang SX, Li X, Liu TF, Xie WB, Yao KT. Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med 2008, 6:55. 10.1186/1479-5876-6-55, 2572589, 18834541.
6. Wang S, Zhou J, Wang XY, Hao JM, Chen JZ, Zhang XM, Jin H, Liu L, Zhang YF, Liu J, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol 2009, 219(1):114-122. 10.1002/path.2575, 19557828.
7. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, Yoshimura H, Tachibana M, Kubota H, Nagasue N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 2000, 6(10):4064-4068.
8. Horikawa T, Yoshizaki T, Sheen TS, Lee SY, Furukawa M. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma. Cancer 2000, 89(4):715-723. 10.1002/1097-0142(20000815)89:4<715::AID-CNCR1>3.0.CO;2-9, 10951332.
9. Wong TS, Kwong DL, Sham JS, Wei WI, Kwong YL, Yuen AP. Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma. Eur J Surg Oncol 2004, 30(5):560-564. 10.1016/j.ejso.2004.02.007, 15135487.
10. Fridman R, Toth M, Chvyrkova I, Meroueh SO, Mobashery S. Cell surface association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 2003, 22(2-3):153-166. 10.1023/A:1023091214123, 12784994.
11. Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, Iftner T, Cuenda A, Chen G. p38{gamma} MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem 2010,
12. Lin LF, Chuang CH, Li CF, Liao CC, Cheng CP, Cheng TL, Shen MR, Tseng JT, Chang WC, Lee WH, Wang JM, et al. ZBRK1 acts as a metastatic suppressor by directly regulating MMP9 in cervical cancer. Cancer Res 2010, 70(1):192-201. 10.1158/0008-5472.CAN-09-2641, 19996286.
13. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S. MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest 2010, 28(1):38-43. 10.3109/07357900802672761, 20001295.
14. Zhao ZS, Wang YY, Ye ZY, Tao HQ. Prognostic value of tumor-related molecular expression in gastric carcinoma. Pathol Oncol Res 2009, 15(4):589-596. 10.1007/s12253-009-9158-9, 19294533.
15. Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 2008, 8:241. 10.1186/1471-2407-8-241, 2528014, 18706098.
16. Provatopoulou X, Gounaris A, Kalogera E, Zagouri F, Flessas I, Goussetis E, Nonni A, Papassotiriou I, Zografos G. Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease. BMC Cancer 2009, 9:390. 10.1186/1471-2407-9-390, 2775750, 19889214.
17. Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck 2007, 29(6):564-572. 10.1002/hed.20561, 17252594.
18. Sakata K, Someya M, Omatsu M, Asanuma H, Hasegawa T, Ichimiya S, Hareyama M, Himi T. The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma. BMC Cancer 2007, 7:229. 10.1186/1471-2407-7-229, 2238761, 18093334.
19. Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998, 82(5):923-930. 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2, 9486583.
20. Yoshizaki T, Sato H, Furukawa M, Pagano JS. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc Natl Acad Sci USA 1998, 95(7):3621-3626. 10.1073/pnas.95.7.3621, 19885, 9520415.
21. Sillanpaa S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, Tammi R, Tammi M, Sironen R, Saarikoski S, Kosma VM. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 2007, 104(2):296-303. 10.1016/j.ygyno.2006.09.004, 17034838.
22. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10(2):7621-7628. 10.1158/1078-0432.CCR-04-1061, 15569994.
23. Sienel W, Hellers J, Morresi-Hauf A, Lichtinghagen R, Mutschler W, Jochum M, Klein C, Passlick B, Pantel K. Prognostic impact of matrix metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer 2003, 103(5):647-651. 10.1002/ijc.10841, 12494473.
24. Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S. Cancer Invest.MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients. Cancer Invest 2010, 28(1):38-43. 10.3109/07357900802672761, 20001295.
25. Tanioka Y, Yoshida T, Yagawa T, Saiki Y, Takeo S, Harada T, Okazawa T, Yanai H, Okita K. Matrix metalloproteinase-7 and matrix metalloproteinase-9 are associated with unfavourable prognosis in superficial oesophageal cancer. Br J Cancer 2003, 89(11):2116-2121. 10.1038/sj.bjc.6601372, 2376843, 14647147.
26. Li Z, Bian LJ, Li Y, Liang YJ, Liang HZ. Expression of protease-activated receptor-2 (PAR-2) in patients with nasopharyngeal carcinoma: correlation with clinicopathological features and prognosis. Pathol Res Pract 2009, 205(8):542-550. 10.1016/j.prp.2009.01.015, 19269113.